Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Imaging experts debate link between CT scans, cancer risk

August 10, 2010
By Greg Frieherr
Greg Frieherr
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 8
Volume 19
Issue 8

Clinical studies examining the potential of CT exposure to cause cancer are under way, but it could be years or even a decade until the results are known, and even then, they may be inconclusive.

Clinical studies examining the potential of CT exposure to cause cancer are under way, but it could be years or even a decade until the results are known, and even then, they may be inconclusive.

A half dozen clinical studies are now enrolling hundreds of thousands of patients in Canada, the UK, Australia, Israel, Sweden, and France with the goal of looking specifically at whether CT is a cause of cancer. But the studies, mostly involving pediatric patients, will take many years to complete. And there is no guarantee the results will be definitive.

Andrew J. Einstein, MD, PhD, an assistant professor of clinical medicine in the departments of radiology and cardiology at New York's Columbia University, examined the current basis for concerns about radiation exposure from CT, noting that none of the data used to support these cautionary arguments involve CT radiation exposure itself. Instead they are largely drawn from studies examining survivors of the atomic bombing of Hiroshima, nuclear industry workers, and exposure of children to radiation in utero. "But it is still important that we do such studies because each additional study provides us with new information and a more complete picture of the issues that we are dealing with," Dr. Einstein said.


ANDREW J. EINSTEIN, MD, PHD

In the meantime, the CT community and the public will be left with only circumstantial data to make or break the connection between CT exams and cancer, a prospect that concerns Cynthia H. McCollough, PhD, director of the CT Clinical Innovation Center at the Mayo Clinic College of Medicine in Rochester, Minn.

Some patients are making poor decisions about their healthcare because of their unjustified fear of CT radiation, Dr. McCollough said, promulgated by data with considerable uncertainty. Despite 60 years of studying the A-bomb survivors, for example, no definitive conclusions have yet been made about the cancer risk at the relatively low doses commonly encountered during CT studies.

"When people say we just don't know what's happening, I disagree," she said. "We know that it is not a big effect. If it is an effect at all, it is a really small effect."

Dr. McCollough has a simple solution to the debate over radiation dose and CT, as it relates to deciding whether to schedule an exam. "If the CT is needed, do it, and do it carefully," she said. "And if it's not needed, don't do it."

References:

Source: 2010 International Symposium for Multidetector CT, International Society for Computed Tomography.

Articles in this issue

Colorectal cancer patients with vitamin D deficiency see worse outcomes
What is the Clinical Role of Induction Therapy in Locally Advanced Squamous Cell Cancer of the Head and Neck?
What is the Clinical Role of Induction Therapy in Locally Advanced Squamous Cell Cancer of the Head and Neck?
Who's News
Sonography better to monitor small testicular lesions
FDA Panel Says No More Avastin in Breast Cancer
Cell-signaling pathway may be new Rx target ER+ breast cancer
Evidence-based pathway plus electronic health records system matches major trials for colorectal cancer treatment outcomes
Ohio cancer center breaks ground on $1 billion addition
Second-Generation TKIs Poised to Succeed Imatinib in Newly Diagnosed CML
Imaging experts debate link between CT scans, cancer risk
From the ONI archives: CML patients’ molecular response to nilotinib continues to deepen over time
Smartphones hustle to maintain pace with rapid rate of change in oncology
Making comparative effectiveness work in cancer care
Geriatric assessment, communication skills essential for older patients
Patients look for answers on Web but trust it less
Recent Videos
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
4 experts in this video
4 experts in this video
Distance and training represent 2 major obstacles to making radiotherapy available to more patients with cancer across the world.
7 experts are featured in this series.
Point-of-care manufacturing, scalable manufacturing, and bringing the cost down [can help].
Louis Potters, MD, FASTRO, FABS, FACR, describes how evidence-based radiation protocols may integrate with novel artificial intelligence software.
The use of enhanced imaging and adaptive radiotherapy has lessened the burden on patients with cancer receiving radiotherapy as treatment.
Related Content
Advertisement

Medical Conference Forum Latest Advances in Healthcare | © Purnomo-Adobe Stock

The Fellow's Playbook: How to Make the Most of Your First Oncology Meeting?

Ariana Pelosci
October 21st 2025
Article

Third-year fellows from Weill Cornell Medicine offer 7 key tips for establishing a foundational understanding of the field at major oncology meetings.


“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

Leveraging Biology to Advance the Small Cell Lung Cancer Treatment Paradigm

Anne Chiang, MD
October 20th 2025
Podcast

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.


Buparlisib/Chemo Does Not Improve OS in PD-1 Recurrent Head and Neck Cancer

Buparlisib/Chemo Does Not Improve OS in PD-1 Recurrent Head and Neck Cancer

Gina Mauro
October 21st 2025
Article

The BURAN trial revealed no overall survival benefit for buparlisib and paclitaxel in recurrent head and neck cancer, despite some response rate improvements.


Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.


The overall survival benefit with the bemarituzumab combination in the phase 3 FORTITUDE-101 trial was consistent across key prespecified subgroups.

Bemarituzumab Regimen Prolongs Survival in Advanced Gastric/GEJ Cancer

Ashling Wahner
October 20th 2025
Article

The overall survival benefit with the bemarituzumab combination in the phase 3 FORTITUDE-101 trial was consistent across key prespecified subgroups.


The confirmed ORR in the investigational arm was 52.3% vs 46.6% in the chemotherapy arm, with respective complete response rates of 10.9% and 8.5%.

Camrelizumab/Famitinib Show First-Line PFS Benefit in Cervical Cancer

Kyle Doherty
October 20th 2025
Article

The confirmed ORR in the investigational arm was 52.3% vs 46.6% in the chemotherapy arm, with respective complete response rates of 10.9% and 8.5%.

Related Content
Advertisement

Medical Conference Forum Latest Advances in Healthcare | © Purnomo-Adobe Stock

The Fellow's Playbook: How to Make the Most of Your First Oncology Meeting?

Ariana Pelosci
October 21st 2025
Article

Third-year fellows from Weill Cornell Medicine offer 7 key tips for establishing a foundational understanding of the field at major oncology meetings.


“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

Leveraging Biology to Advance the Small Cell Lung Cancer Treatment Paradigm

Anne Chiang, MD
October 20th 2025
Podcast

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.


Buparlisib/Chemo Does Not Improve OS in PD-1 Recurrent Head and Neck Cancer

Buparlisib/Chemo Does Not Improve OS in PD-1 Recurrent Head and Neck Cancer

Gina Mauro
October 21st 2025
Article

The BURAN trial revealed no overall survival benefit for buparlisib and paclitaxel in recurrent head and neck cancer, despite some response rate improvements.


Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.


The overall survival benefit with the bemarituzumab combination in the phase 3 FORTITUDE-101 trial was consistent across key prespecified subgroups.

Bemarituzumab Regimen Prolongs Survival in Advanced Gastric/GEJ Cancer

Ashling Wahner
October 20th 2025
Article

The overall survival benefit with the bemarituzumab combination in the phase 3 FORTITUDE-101 trial was consistent across key prespecified subgroups.


The confirmed ORR in the investigational arm was 52.3% vs 46.6% in the chemotherapy arm, with respective complete response rates of 10.9% and 8.5%.

Camrelizumab/Famitinib Show First-Line PFS Benefit in Cervical Cancer

Kyle Doherty
October 20th 2025
Article

The confirmed ORR in the investigational arm was 52.3% vs 46.6% in the chemotherapy arm, with respective complete response rates of 10.9% and 8.5%.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.